Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients With Heart Failure With or Without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial.
Fiche publication
Date publication
août 2024
Journal
American journal of nephrology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Weir MR, Rossignol P, Pitt B, Lund LH, Coats AJS, Filippatos G, Perrin A, Waechter S, Budden J, Kosiborod M, Metra M, Boehm M, Ezekowitz JA, Bayes-Genis A, Mentz RJ, Ponikowski P, Senni M, Castro-Montes E, Nicolau JC, Parkhomenko A, Seferovic P, Cohen-Solal A, Anker SD, Butler J
Lien Pubmed
Résumé
Renin-angiotensin-aldosterone system inhibitor (RAASis; including mineralocorticoid receptor antagonists [MRAs]) benefits are greatest in patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD); however, the risk of hyperkalemia (HK) is high.
Référence
Am J Nephrol. 2024 08 19;: